Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling

Abstract excerpt

Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic prevalence between 1:400 and 1:1,000 individuals, is the third most common cause of end stage kidney disease after diabetes mellitus and hypertension. Over the last 3 decades there has been great progress in understanding its pathogenesis. This allows the stratification of therapeutic targets into four levels, gene mutation and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomedical Research and Pathophysiology
• Share to Genetic and Kidney Cyst Diseases
• Share to Renal Diseases and Glomerulopathies